Video
Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer
Author(s):
Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.
Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.
The cleanest data is for pembrolizumab (Keytruda) from the KEYNOTE-045 study because there was an overall survival (OS) benefit independent of PD-L1 expression, explains Friedlander.
According to Friedlander, there is rationale to give atezolizumab (Tecentriq) in this setting when looking at the intent-to-treat population.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
